Department of Surgery and Cancer, Imperial College London, London, UK; Imperial Vascular Unit, Imperial College Healthcare NHS Trust, London, UK.
Department of Surgery and Cancer, Imperial College London, London, UK; Imperial Vascular Unit, Imperial College Healthcare NHS Trust, London, UK.
J Vasc Surg. 2021 Nov;74(5):1447-1455. doi: 10.1016/j.jvs.2021.04.027. Epub 2021 Apr 30.
Thoracic endovascular aortic repair with a scallop design (scallop-TEVAR) is a useful treatment strategy to extend the proximal landing zone (PLZ), while maintaining perfusion to one or more of the supra-aortic trunks (SATs) when treating aortic pathology with an unfavorable PLZ. The durability of this approach with the Bolton Relay scallop endograft (Terumo Aortic, Sunrise, Fla) has not been established.
A retrospective review of prospectively collected data on consecutive patients that received scallop-TEVAR in zones 0 to 2 at a tertiary aortic unit was undertaken. The main outcome was durability, characterized by survival estimates, freedom from reintervention to the thoracic aorta and PLZ, migration and aneurysm sac regression.
Between 2009 and 2019, 38 patients (71% male; median age, 70 years) underwent scallop-TEVAR for thoracic aortic pathology (n = 28, 74%) or as a part of thoracoabdominal aneurysm repair (n = 10 [26%]). The use of scallop-TEVAR significantly extended the PLZ (median, 5 mm preoperative PLZ vs 26 mm extended PLZ; P = .0001). A total of 41 SATs were perfused with a scallop, including the left subclavian artery (n = 25), left common carotid artery (n = 6), neo/innominate artery (n = 4), left subclavian artery, and vertebral artery (n = 1), innominate artery, and left common carotid artery (n = 2) in conjunction with 15 extra-anatomical bypasses. The PLZ was at Ishimaru zone 0 and 1 in 6 cases (16%), respectively, and zone 2 in 26 cases (68%). Technical success was 98%. The 30-day mortality was 5% (2/38; 1 death from myocardial infarction and 1 from multiorgan failure). A minor stroke occurred in three patients (8%) and temporary spinal cord ischemia in two patients (5%). The median follow-up was 4.5 years (range, 0-10.53 years) during which two patients (5%) developed type Ia endoleak and required intervention to the PLZ (one from device-related migration and one from disease progression). All-cause and aorta-related survival were 72% and 85% and freedom from thoracic and PLZ reintervention was 92% and 97%, respectively. There were no cases of early or late thoracic aortic rupture, retrograde type A aortic dissection or SAT occlusion.
Scallop-TEVAR offers a less invasive treatment option to extend the seal zone in selected patients with an unfavorable PLZ, allowing for a durable repair in terms of overall survival and reintervention. Periprocedural stroke remains a principle concern.
带扇贝设计的胸主动脉腔内修复术(扇贝-TEVAR)是一种有用的治疗策略,可延长近端着陆区(PLZ),同时在治疗具有不利 PLZ 的主动脉病变时保持对一个或多个主动脉弓分支(SAT)的灌注。尚未确定使用 Bolton Relay 扇贝血管内移植物(Terumo Aortic,Sunrise,佛罗里达州)的这种方法的耐久性。
对在三级主动脉单位接受 0 至 2 区扇贝-TEVAR 的连续患者的前瞻性收集数据进行回顾性分析。主要结果是耐用性,其特征是通过生存估计、胸主动脉和 PLZ 再干预、迁移和动脉瘤囊退缩来衡量。
2009 年至 2019 年,38 例患者(71%为男性;中位年龄 70 岁)因胸主动脉病变(n=28,74%)或作为胸腹主动脉瘤修复的一部分(n=10[26%])接受了扇贝-TEVAR。扇贝-TEVAR 显著延长了 PLZ(中位数,术前 PLZ 为 5mm 与延长的 PLZ 为 26mm;P=0.0001)。共有 41 个 SAT 被扇贝灌注,包括左锁骨下动脉(n=25)、左颈总动脉(n=6)、新/无名动脉(n=4)、左锁骨下动脉和椎动脉(n=1)、无名动脉和左颈总动脉(n=2)以及 15 个额外的解剖旁路。PLZ 在 Ishimaru 0 区和 1 区的分别为 6 例(16%)和 26 例(68%)。技术成功率为 98%。30 天死亡率为 5%(2/38;1 例死于心肌梗死,1 例死于多器官衰竭)。3 例(8%)发生小中风,2 例(5%)发生短暂性脊髓缺血。中位随访时间为 4.5 年(0-10.53 年),其中 2 例(5%)发生 Ia 型内漏,需要对 PLZ 进行干预(1 例因器械相关迁移,1 例因疾病进展)。全因生存率和主动脉相关生存率分别为 72%和 85%,胸主动脉和 PLZ 再干预的无复发率分别为 92%和 97%。无早期或晚期胸主动脉破裂、逆行性 A 型主动脉夹层或 SAT 闭塞的病例。
扇贝-TEVAR 为具有不利 PLZ 的选定患者提供了一种侵入性较小的治疗选择,可实现总体生存和再干预方面的持久修复。围手术期中风仍然是一个主要关注点。